Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast,

Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 - 2026

The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research. The report “Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.

Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.

Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.